Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study.

ABSTRACT:

Introduction

Recent real-world studies compared effectiveness and safety of enzalutamide (ENZA) and abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC). The growing evidence needs further substantiation with long-term data. This study, the first to use German data, investigated cardiovascular (CV) event risk and overall survival (OS) in patients initiating ENZA or AA. AA (2012) and ENZA (2014) are widely used for mCRPC in Germany.

Methods

This retrospective study used data of chemotherapy-naïve patients with mCRPC on ENZA or AA (2012-2020) from two German claims databases (AOK PLUS and GWQ ServicePlus). The primary endpoint was time to first CV event (CV-related hospitalization) analyzed via a meta-analysis of Cox proportional hazard models o

SUBMITTER: Merseburger AS 

PROVIDER: S-EPMC11929622 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature